Page 409«..1020..408409410411..420430..»

New director of IICT takes charge – The Hindu

Posted: June 13, 2022 at 2:26 am

D. Srinivasa Reddy took charge as the new director of the Indian Institute of Chemical Technology (IICT) in Hyderabad on Friday. He took charge from NGRI director V.M. Tiwari officiating as the director additional in-charge since December 2021.

Prior to this, Dr. Reddy was the director of CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu, since 2020, and director (additional charge) CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, since February 2022.

As full time director of CSIR-IICT, Dr. Reddy will also hold the additional charge of the post of director of CSIR-IIIM, Jammu and director, CSIR-CDRI, Lucknow.

He completed his graduation and post-graduation from Osmania University before completing his PhD in synthetic organic chemistry from the University of Hyderabad under the supervision of Professor Goverdhan Mehta in 2000. He did his post-doctoral work at the laboratories of Sergey A. Kozmin of the University of Chicago and Jeffrey Aub of the University of Kansas during 2001-03.

Dr. Reddy is the recipient of J.C. Bose Fellowship, Shanti Swarup Bhatnagar Prize in Chemical Sciences, Fellow of the Indian Academy of Sciences, India (FASc) and Fellow of the National Academy of Sciences, India (FNASc), said an official release.

Go here to see the original:
New director of IICT takes charge - The Hindu

Posted in Integrative Medicine | Comments Off on New director of IICT takes charge – The Hindu

Mistletoe and the Emerging Future of Integrative Oncology – Verve Times

Posted: June 13, 2022 at 2:26 am

In this interview, Dr. Nasha Winters, coauthor of Mistletoe and the Emerging Future of Integrative Oncology, reviews some of the benefits of this ancient herb in the modern world of oncology. Winters is herself a cancer survivor, so this topic is close to her heart.

Im coming on 30 years out of a death sentence, a terminal cancer diagnosis, she says, and still to this day get met with so much resistance to what Ive learned for myself, and for thousands, if not tens of thousands, of other patients directly, as well as way more than that, indirectly, through the training of their physicians

My crazy controversy is that I focus more on the human organism and the health of that terrain versus the condition, the disease or the label that overlays that person.

Mistletoe, a semi-parasitic plant that grows in the branches of trees all over the world, has been used as a herbal medicine for thousands of years for conditions such as epilepsy, spleen disorders, pain and rheumatic conditions.

Just over 100 years ago, in 1917, Rudolf Steiner, a philosopher with incredibly keen observation skills, noticed the mistletoe looks a lot like a tumor, and proposed it might have anticancer properties. Many vitalistic medical practices, such as Ayurveda, Chinese medicine, naturopathy and homeopathy, for example, use the doctrine of signatures, which is what Steiner was suggesting.

For instance, you look at a walnut and it kind of looks like a brain and we think, I wonder if thats any good for the brain? And sure enough, we find some significance in how it impacts the brain. Or things like lungwort. When you look at it, it looks like a lung and weve learned that this herbal medicine is very helpful for lung conditions, Winters says.

A Swiss doctor named Ita Wegman applied Steiners observation of mistletoe to see how it would impact a patient with cancer, and the plant has since enjoyed over 100 years of consistent application in oncology, both standalone and as adjuvant support.

Interestingly enough Steiner understood that you needed to harvest different components of the plant berries that bloom in the winter, which is very abnormal, and the leaves that grow in the summer and grow inward.

It has a very interesting behavior compared to other plants, and that was an observation of how cancer works as well. It goes against the rhythm. It grows out of sync with the organism. That is very much what he recognized.

And as such, he harvested the plant and aspects of the plant at different times, blended it, and then took a particular extract from it. He also noted that it needed to be injected, because you need to remember, 100 years ago we didnt know about lectins, we didnt know about viscotoxins, yet somehow, he understood that you needed to inject it to get the anticancer benefit.

You could take the full tincture. You could take it in other ways, and it has a lot of other medicinal impacts, but then it doesnt have the anticancer impacts, the reason being, weve learned or at least we suspect, because were still learning is that those lectins and things get broken down in our GI tract and they dont get into the bloodstream; they dont access the immune system in the way they need to

According to Winters, mistletoe is likely to be useful as an adjunct therapy for all cancers, and she, along with several other doctors, has been training physicians on how to use mistletoe for several years now.

One of our physicians has been using mistletoe for 45 years in his practice, and what weve seen clinically, and what the research suggests, is that this therapy, it has always been about using it with others. It plays very well with others.

It was never really developed to be a standalone therapy, though believe me, weve seen impact with that as well. And it has virtually no contraindications with any of our standard of care therapies. So, we can literally inject this into a patient the morning before they go into a surgery, or they can start on this therapy the very day theyre going to start a round of chemotherapy or radiation.

It bypasses first phase detox pathways of the liver, so it doesnt interact, intervene, speed up or slow down detox processes that could otherwise cause some adverse events, or change the desired effect of a certain medication, herbal intervention or dietary intervention.

In fact, mistletoe has been shown to enhance other interventions. Even the most toxic treatments seemingly work better and with fewer adverse effects when combined with mistletoe.

This should be utilized, in my personal opinion, with every patient going through a standard of care approach to just enhance their experience with treatment, she says.

There are a lot of things that we kind of have to be careful with but mistletoe, in my experience, and that of my colleagues, is that this is probably the least harmful and least contraindicated substance and therapy Ive ever had the privilege of working with. Its pretty extraordinary and rare to find something that is this applicable to the masses

As I said, it has over 100 years of continuous use, and has over 250 very good randomized studies It just completed a Phase 1 clinical trial at Johns Hopkins in the United States as an IV application for solid tumors, and is getting ready to be moved into a Phase 2 clinical trial.

It is the most studied integrative oncology therapy in the world, and it is utilized in upwards of 60% to 80% of all cancer patients in Europe. In parts of South and Central America, all over Southeast Asia and India, in different parts of Europe, this is just part of their medical system Its just in the United States where we have a little bit of resistance to embracing it into our conventional medical system

As a naturopathic physician whos been practicing integrative oncology for some time and who has teachers, mentors, colleagues from all over the world, some of the most powerful anticancer therapies Ive seen that are beneficial even to the standard of care model of treatment things like artesunate, curcumin, quercetin, green tea extract, all of those in intravenous forms have been taken out of our ability to use here in the United States.

Do my colleagues still find workarounds to get access to these very important medicines? Absolutely they do, but they have to tread very carefully and very lightly. But again, you go north of the border or south of the border and you have no problem accessing these therapies. Or go to Europe and this is what Ive been doing for the last two years.

These treatments that weve had great success with have been plucked out of our ability to access easily, readily, legally, so were now having to send our patients abroad for them to actually get good cancer care.

Thats whats really devastating to me. So, another part of my purpose and mission is to build an in-house residential research institute and integrative cancer hospital right here on our soil so we dont lose access and patients dont lose access [to helpful remedies].

Winters is currently building that research institute in Arizona, which will be funded entirely by private donations and research grants. Thousands of patients are anxiously waiting for the doors to open. When asked if she isnt worried our pro-pharma agencies might shut them down, she replies:

We will be doing all of our due diligence to let people know that these are not FDA approved therapies, that people are coming into a research environment. Theyre either paying cash or theyre getting grants based on their financial ability to help them cover this care.

Were doing it in a pretty open-minded medical state; Arizona has one of the broadest scopes of practice in the country. And were also very close to our southern border with Mexico, so that if we do come up against someone shutting down one of our therapies for a bit, we are able to take our patients across the border to a little sister clinic to keep the continuity of care.

We dont anticipate that happening because people are coming as a buyer beware. Theyre coming being well-informed about who we are and what were about. And frankly, we get thousands of inquiries a month from all over the world looking for this approach. The patients will drive this home.

Its a mighty David versus Goliath story, especially now, but I also think the time is now because we have these acts, like the Right to Try Act, and because we do have more and more patients facing this diagnosis with grim outcomes.

And, a study that came out in the last year that looked at 17 years worth of conventional cancer treatments found that, overall, of the 96 different drugs they looked at, the average survival rate was 2.4 months. That is the reality and this is whats driving the clinical oncologists from around the world to sign up and take my course

So, there is this massive kind of underground movement thats starting to sprout and come above ground. Thats happening. And frankly, mistletoe is one of the vehicles for that to happen Instead of trying to fix the model, were just creating a new one.

Another potential back door is to convince insurance companies that this is in their best interest. Mistletoe is a natural remedy and therefore cannot be patented, so theres no incentive for the drug companies to pursue it. But insurance companies may support its use once they realize how much money they can save on hospitalizations, drug coverage and everything else.

Your immune system and metabolic function are both integral parts of addressing cancer, and mistletoe works on both. Its important to recognize, however, that its not a magic bullet. If youre eating a standard American diet and are metabolically dysfunctional, mistletoe is not going to be as effective as for someone who is also eating a healthy whole food diet and supporting their health in other ways.

That said, mistletoe is an immunomodulator. Immune therapies are all the rage right now, with a majority of research dollars being funneled into them. Yet the effectiveness rate for these therapies is less than 20%. In other words, theyre hardly a cure.

A lot of folks have heard of Jimmy Carters melanoma story that had metastasized to his brain. He took this immune drug, Keytruda. Thats a checkpoint inhibitor. The most common drugs youll hear about are things like Opdivo, Keytruda, PD-1, PDL1 inhibitors, those are checkpoint inhibitors, or CTLA-4 inhibitors, also a type of checkpoint inhibitor.

These are drugs that kind of pull the breaks off your immune system to go hog wild in treating the cancer. Now that seems like a great idea unless you have underlying metabolic dysfunction, right? Hello! And then, if you have an underlying autoimmune condition, you are also someone whos likely going to have a not so positive response to these medications.

What I love about mistletoe is it comes in and it modulates that teeter-totter. It doesnt take the breaks off and make it go hog wild, and it doesnt suppress. Its kind of adaptogenic in some ways. So, it behaves a little bit like a smart drug, in that it can sort of match itself to the individual.

It is not a protocol, its a patient-driven process in that we look at the persons gender, we look at the tumor type, the tumor stage, the general condition of the patient, and then we consider the most appropriate host tree. The most common are the pine, the fir, and the apple tree hosts. Mistletoe [from these trees] tends to have the highest lectin content that have the highest anti-cancer content.

Then we look at the dosing frequency, and if were going to do it subcutaneous, intravenous, intratumoral, intraperitoneal, et cetera, depending on where you live in the world and how were going to pair it with other therapies, if at all. So, it is based totally on the individual and the individuals response.

We want the patient to have a little local reaction if theyre injecting it. We want it to get a little redness, irritation and itchiness and maybe tenderness. We want it to raise the bodys temperature a little bit The point is, we want to create this cytokine release at a very low-grade level. Whereas when we bring on an immune drug like Keytruda, it creates a cytokine release at an explosive level that can sometimes be fatal for patients.

Similar to drugs, mistletoe also has a systemic effect. It doesnt target a specific receptor site. Instead, its a systemic terrain-centric approach. In its mechanisms of action, its engaging with B-cells, T-cells, natural killer (NK) cells.

It will basically calm those that are acting overzealous, to prevent an excessive immune reaction, and activate those that are dormant or underperforming. Mistletoe also reduces inflammation, lowering your levels of C-reactive protein, interleukin-6, homocysteine, liver enzymes and more.

It also lowers vascular endothelial growth factor (VEGF), which can be important for certain cancers, and it lowers blood sugar and insulin. Winters also suspects mistletoe may be upregulating both the endorphin and the endocannabinoid system, so youre getting stress modulation as well.

So, its hitting all of what we call The Terrain 10, from my previous book, The Metabolic Approach to Cancer. I find that mistletoe tends to hit every one of those including epigenetic expression clean up of DNA.

We use it for people whove gone through radiation. Well use it as a DNA stabilizer. Well use it if people have taken a course of Cipro [and other fluoroquinolones] to help clean up the metabolic mayhem, the DNA damage that they cause. We know that it has some impact on insulin and IGF-1.

In our book, we have hundreds of references to all of the different mechanisms of action. My colleague, Dr. Paul Faust, [has written] a beautiful chapter on its direct impact on the immune system and all the nuances of that.

That chapter alone will illuminate for so many people why this therapeutic support and this therapeutic intervention is so helpful for the cancer patient, for prevention of cancer, for cleanup after cancer treatment

And the synergy, when you pair mistletoe with hyperthermia, like so many of my colleagues in Europe have been doing for the past 50 years, talk about the biggest bang for your buck. We see some pretty extraordinary outcomes.

Ive had patients go to Europe with Stage 4 [cancer], metastatic disease everywhere, getting IV mistletoe along with local, regional and whole body high-heat hyperthermia that have put their cancer into complete remission in many cases, but at the very least, turning it back into a manageable disease process, and even more interesting, increasing the responsivity to other therapies again.

The good news is the number of doctors trained in this therapy is growing, and the treatment itself is only between $200 and $300 a month, so its highly affordable while also being highly effective. I think it would be beyond irrational not to integrate this into any cancer therapy youre considering.

Again, for cancer, oral supplementation is ineffective, as the lectins responsible for the anticancer effects are broken down in your GI tract and therefore cant enter your bloodstream.

The Physicians Association for Anthroposophic Medicine (PAAM) sponsors Winters mistletoe trainings. While most are held in person, theres now also a course available online for licensed physicians. There are plans to take a group of physicians to Europe for immersive in-hospital training in the fall of 2023. Heres a list of resources where you can find more information:

AnthrosophicMedicine.org offers articles, research, books, webinars and more. To locate a clinician trained in the proper administration of mistletoe, see PAAMs health provider directory.

Clinicians interested in training, visit the education section of PAAMs website. The next annual training conference will be held in Loveland, Colorado, April 29 through May 6, 2023.

Metabolic Terrain Institute of Health (MTIH) is the not-for-profit association cofounded by Winters that is building a research hospital in Arizona. MTIH also offers a master course for practitioners, and grants to help patients access these therapies. Certified practitioners can be found on terrain.network.

These practitioners include medical doctors and oncologists who have been taught Winters methodology of testing, assessing and treating cancer (which includes but is not limited to mistletoe therapy). MTIH certified practitioners are also listed on DrNasha.com.

Mistletoe-therapy.org is a European website that offers helpful information for patients and scientific papers directed at clinicians.

A load of resources are found on the books website: http://www.themistletoebook.com. Proceeds from this book go to fund clinical research and contribute to physician training.

Last but certainly not least, youll want to pick up a copy of Mistletoe and the Emerging Future of Integrative Oncology. Its an excellent book.

Read original article here

Originally posted here:
Mistletoe and the Emerging Future of Integrative Oncology - Verve Times

Posted in Integrative Medicine | Comments Off on Mistletoe and the Emerging Future of Integrative Oncology – Verve Times

First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting – Newswise

Posted: June 13, 2022 at 2:24 am

Newswise LOS ANGELES (June 9, 2022) --Investigators from Cedars-Sinai will present the latest novel stem cell and regenerative medicine research at the International Society for Stem Cell Research (ISSCR) Annual Meeting, which is being held in person and virtually June 15-19 in San Francisco.

At this years scientific forum,Clive Svendsen, PhD, a renowned scientist and executive director of theCedars-SinaiBoard of Governors Regenerative Medicine Institute, willassume the role as treasurerfor the organization. In this position, he will be working with leading scientists, clinicians, business leaders, ethicists, and educators to pursue the common goal of advancing stem cell research and its translation to the clinic.

Along with taking on this leadership role, Svendsens work on a combination stem cell-gene therapy for the treatment of amyotrophic lateral sclerosis, afatal neurological disorder known as ALS or Lou Gehrig's disease, was selected as a Breakthrough Clinical Advances abstract and one ofthe years most compelling pieces of stem cell science. Svendsen will present data from the first spinal cord trial and a synopsis of the ongoing cortical trial and the potential impact this may have on this devastating disease.

The breakthrough oral session, A new trial transplanting neural progenitors modified to release GDNF into the motor cortex of patients with ALS, takes place on Thursday, June 16, from 5:15 to 7 p.m. The presentation is part of the Biotech, Pharma and AcademiaBringing Stem Cells to Patients Clinical Applications track.

Through this highly collaborative work, we hope to develop new therapeutic options for patients with such a debilitating and deadly disease, said Svendsen, who is also the Kerry and Simone Vickar Family Foundation Distinguished Chair in Regenerative Medicine.

All abstracts are embargoed until the start of each individual presentation.

Additional noteworthy presentations featuring Cedars-Sinai investigators at ISSCR 2022 include:

FollowCedars-Sinai Academic Medicineon Twitterfor more on the latest basic science and clinical research from Cedars-Sinai.

Excerpt from:
First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise

Posted in Stem Cell Research | Comments Off on First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting – Newswise

Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants – Euronews

Posted: June 13, 2022 at 2:24 am

Researchers in the UK have developed a biodegradable hydrogel that could help repair the damage caused by heart attacks.

The gel is used as a binding agent to inject stem cells into the heart. These cells can then regenerate and rebuild areas where the tissue is damaged.

So far, the gel has only been tested in healthy mice. But scientists at the University of Manchester say its showing promising results and they hope it can become a key part of future regenerative treatments.

According to the World Health Organization (WHO) and the Lancet Burden of Disease, over nine million people each year die from coronary heart disease, the most common cause of heart failure, despite significant advances in heart surgery.

During a heart attack, blood and oxygen are cut off from the heart, which can cause muscle cells to die. Depending on the severity of the damage, patients can require a heart transplant - a complicated, invasive, and risky procedure.

The team at the University of Manchester is hoping the new gel technology can ultimately improve regenerative treatments and avoid heart transplants altogether.

Stem cell surgery has already been widely used to generate tissue. In Switzerland, surgeons have grown stem cells into cartilage and transplanted them into damaged knees.

However, successes with the heart have been more elusive. In the past, surgeons have tried to inject stem cells directly into the heart, but the cells have not survived.

"The challenges in injecting these cells into a beating heart is that the heart is a mechanical structure and that the cells, if they're injected alone, find it very difficult to find an anchor, said Professor James Leiper, Associate Medical Director at the British Heart Foundation, which funded the research.

This hydrogel is an exciting potential mechanism that we could use to really harness the regenerative capacity of stem cells".

The team at the University of Manchester says the gel can be safely injected into the beating heart to act as a scaffold for stem cells to grow new tissue.

The gel is made of chains of amino acids called peptides, the building blocks of proteins.

To prove it could work in a living heart, the team injected the gel with a fluorescent tag into the hearts of healthy mice.

The fluorescent tag revealed that the gel remained in the heart for two weeks, while ultrasounds and electrocardiograms showed the injection was safe.

Lead researcher Katharine King says this shows the cells can be held inside the hearts long enough for the stem cells to start growing.

"It's looking very promising, the way that it would stay there and be able to hold the cells there long enough for them to kind of integrate into the heart," she said.

The researchers now plan to trial the gel in mice straight after a heart attack, to see whether the heart cells can develop new muscle tissue and help restore the hearts ability to pump efficiently.

Only if trials on animals are successful will scientists be able to conduct further clinical studies to assess whether the gel can safely and effectively be used in humans, a process that typically takes several years.

"If the benefits are replicated in further research and then in patients, these gels could become a significant component of future treatments to repair the damage caused by heart attacks," Leiper said.

For more on this story, watch the video in the media player above.

Read this article:
Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants - Euronews

Posted in Stem Cell Research | Comments Off on Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants – Euronews

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery – Business Wire

Posted: June 13, 2022 at 2:24 am

CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening.

Axols human iPSC-derived ventricular cardiomyocytes are manufactured at scale according to strict quality control standards using ISO 9001-accredited quality management systems, providing a continuous source of cells from the same genetic background for use in multiple experiments. This offers a physiologically relevant in vitro research model of human heart cells to reliably and repeatably test drug candidates for cardiotoxicity at scale.

With the advent of human iPSC-derived cardiomyocytes, the US Federal Food and Drug Administration Agency (FDA) launched a working group to assess the utility of these cells in reproducing cardiotoxicity in a dish, known as CiPA*. The assay tests cells with 28 compounds that are known to be cardiotoxic and induce the fatal arrhythmia Torsades de Pointes. Clyde Biosciences, a CRO that specializes in cardiotoxicity assays, used this assay to validate Axols cardiomyocytes for cardiac safety testing. Using these cells could help researchers to identify unsuitable drug candidates earlier in the drug discovery process and improve the number of promising pre-clinical drug candidates that translate through to clinical trials and to patients.

Liam Taylor, CEO, Axol Bioscience, said: Scientists need cells and reagents they can rely on to make meaningful assessments of drug candidate toxicity, before progressing candidates to the clinic.

Were both excited and proud to demonstrate the suitability of our human iPSC-derived ventricular cardiomyocytes for toxicity testing. Axols stringent quality control standards mean we have the capability to produce reliable, validated cells that scientists can use to assess a compounds cardiac liability and, ultimately, help to improve the drug discovery process.

Prof. Godfrey Smith, CSO, Clyde Biosciences, added: As a core member of the CiPA initiative, were pleased to have supported Axols cell development and helped the team assess the performance of its cardiomyocytes. Having run the CiPA protocol on Clydes proprietary CellOPTIQ platform, and provided analysis and interpretation of the data, we confirm our data indicates that Axols cardiomyocytes meet the requirements for predictive in vitro pro-arrhythmia screening.

For further information about Axols human iPSC-derived cardiomyocytes, please visit: https://axolbio.com/cells/cardiovascular-system/

Dr. Jamie Bhagwan, Group Leader, Axol Bioscience will present data describing the development of Axols iPSC-derived cardiomyocytes alongside Clyde Biosciences Prof. Godfrey Smith at a free-to-attend webinar on June 9th, at 6 PM BST / 1 PM ET / 10 AM PT. Register here: https://register.gotowebinar.com/register/1085358037527496720?hss_channel=lcp-

Axol will also be attending the International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, USA from June 1518, 2022. Visit booth 440 to learn more.

* About CiPA: https://cipaproject.org/about-cipa/#About

Here is the original post:
Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Business Wire

Posted in Stem Cell Research | Comments Off on Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery – Business Wire

Fasting has pros and cons for muscle repair in mice – Futurity: Research News

Posted: June 13, 2022 at 2:24 am

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Fasting sends muscle stem cells into a deep resting state that slows muscle repair but also makes them more resistant to stress, according to a study of laboratory mice.

The protective effect can also be achieved by feeding the mice high-fat, low-carbohydrate foodalso known as a ketogenic dietthat mimics how the body responds to fasting, or by giving the animals ketone bodies, the byproducts that occur when the body uses fat as an energy source.

The research explores how the body responds in times of deprivation and plenty and gives clues about the effect of aging on the ability to regenerate and repair damaged tissue. Although the study focused on muscle stem cells, the researchers believe the findings are applicable to other types of tissue throughout the body.

As we age, we experience slower and less complete healing of our tissues, says Thomas Rando, professor of neurology and neurological sciences at Stanford University. We wanted to understand what controls that regenerative ability and how fasting impacts this process. We found that fasting induces resilience in muscle stem cells so that they survive during deprivation and are available to repair muscle when nutrients are again available.

Rando, who recently accepted a position as the director of the Broad Stem Cell Research Center at UCLA, is the senior author of the study in Cell Metabolism. Instructor Daniel Benjamin and graduate student Pieter Both are the lead authors of the study.

Its been well documented that long-term caloric restriction extends the lifespan and promotes the overall health of laboratory animals, but it is difficult for people to maintain a very-low-calorie diet for months or years. Periodic fasting has been explored as another way to obtain the health benefits of caloric restriction, but the effects of intermittent fasting on the body and its ability to regenerate damaged or aging tissues have not been well studied.

Fasting or, alternatively, eating a ketogenic diet high in fat and low in carbohydratesa popular weight-loss techniquecauses the body to enter a state called ketosis, in which fat is the primary energy source. Ketone bodies are the byproducts of fat metabolism.

The researchers found that mice that had fasted between 1 and 2.5 days were less able than non-fasting animals to regenerate new muscle in their hind legs in response to injury. This reduced regenerative capacity persisted for up to three days after the mice began feeding again and returned to a normal body weight; it returned to normal within one week of the end of the fast.

Further research showed that muscle stem cells from fasting animals were smaller and divided more slowly than those from non-fasting animals. But they were also more resilient: They survived better when grown on a lab dish under challenging conditions including nutrient deprivation, exposure to cell-damaging chemicals, and radiation. They also survived transplantation back into animals better than those from non-fasting animals.

Usually, most laboratory-grown muscle stem cells die when transplanted, Rando says. But these cells are in a deep resting state we call ketone-induced deep quiescence that allows them to withstand many kinds of stress.

Muscle stem cells isolated from non-fasting animals and then treated with a ketone body called beta-hydroxybutyrate (BHB) displayed a similar resilience as did those from fasting animals, the researchers found. Additionally, muscle stem cells isolated from mice fed a ketogenic diet, or a normal diet coupled with injections of ketone bodies, displayed the same characteristics of the deeply quiescent stem cells from fasting animals.

Finally, the researchers isolated muscle stem cells from old mice that had been treated with ketone bodies for one week. Previous research in Randos lab showed that these aged muscle stem cells grew more poorly in the laboratory than muscle stem cells from younger animals. But treatment with the ketone bodies allowed the old muscle stem cells to survive as well as their younger counterparts.

Although more research needs to be done, the results are intriguing, the researchers say.

Cells evolved to exist in times of abundance and in times of deprivation, Rando says. They had to be able to survive when food was not readily available. Ketone bodies arise when the body uses fat for energy, but they also push stem cells into a quiescent state that protects them during deprivation. In this state, they are protected from environmental stress, but they are also less able to regenerate damaged tissue.

Balancing these outcomes might one day help combat normal aging and enhance stem cell function throughout the body, the researchers speculate.

It would be beneficial if the effects of fasting on stem cells could be attained through ketone bodies, supplanting the need to fast or to eat a ketogenic diet, Rando says. Perhaps it may be possible to eat normally and still get this increased resilience.

The National Institutes of Health, the Buck Institute for Research on Aging, and the Department of Veterans Affairs supported the work.

Researchers from UC Berkeley, the Veterans Affairs Palo Alto Health Care System, and the Mondor Institute for Biomedical Research in France are coauthors of the study.

Source: Stanford University

Here is the original post:
Fasting has pros and cons for muscle repair in mice - Futurity: Research News

Posted in Stem Cell Research | Comments Off on Fasting has pros and cons for muscle repair in mice – Futurity: Research News

Scientists have figured out how to reverse the ageing process in mice. Now theyre turning their attention to humans – 7NEWS

Posted: June 13, 2022 at 2:22 am

In molecular biologist David Sinclairs lab at Harvard Medical School, old mice are growing young again.

Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset ageing cells in mice to earlier versions of themselves.

In his teams first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offsprings.

For more Health & Wellbeing related news and videos check out Health & Wellbeing >>

Its a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age, said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

If we reverse ageing, these diseases should not happen.

We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimers in your 90s. Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

This is the world that is coming. Its literally a question of when and for most of us, its going to happen in our lifetimes, Sinclair told the audience.

Whitney Casey, an investor who is partnering with Sinclair to create a do-it-yourself biological age test, said Sinclair wants to make ageing a disease.

His research shows you can change ageing to make lives younger for longer, she said.

While modern medicine addresses sickness, it doesnt address the underlying cause, which for most diseases, is ageing itself, Sinclair said.

We know that when we reverse the age of an organ like the brain in a mouse, the diseases of ageing then go away. Memory comes back, there is no more dementia, she said.

I believe that in the future, delaying and reversing ageing will be the best way to treat the diseases that plague most of us.

In Sinclairs lab, two mice sit side by side. One is the picture of youth, the other gray and feeble.

Yet they are brother and sister, born from the same litter - only one has been genetically altered to age faster.

If that could be done, Sinclair asked his team, could the reverse be accomplished as well? Japanese biomedical researcher Shinya Yamanaka had already reprogrammed human adult skin cells to behave like embryonic or pluripotent stem cells, capable of developing into any cell in the body.

The 2007 discovery won the scientist a Nobel Prize, and his induced pluripotent stem cells, soon became known as Yamanaka factors.

However, adult cells fully switched back to stem cells via Yamanaka factors lose their identity.

They forget they are blood, heart and skin cells, making them perfect for rebirth as cell du jour, but lousy at rejuvenation.

You dont want Brad Pitt in The Curious Case of Benjamin Button to become a baby all at once; you want him to age backward while still remembering who he is.

Labs around the world jumped on the problem. A study published in 2016 by researchers at the Salk Institute for Biological Studies in La Jolla, California, showed signs of ageing could be expunged in genetically aged mice, exposed for a short time to four main Yamanaka factors, without erasing the cells identity.

But there was a downside in all this research: In certain situations, the altered mice developed cancerous tumors.

Looking for a safer alternative, Sinclair lab geneticist Yuancheng Lu chose three of the four factors and genetically added them to a harmless virus.

The virus was designed to deliver the rejuvenating Yamanaka factors to damaged retinal ganglion cells at the back of an aged mouses eye. After injecting the virus into the eye, the pluripotent genes were then switched on by feeding the mouse an antibiotic.

The antibiotic is just a tool. It could be any chemical really, just a way to be sure the three genes are switched on, Sinclair said.

Normally they are only on in very young developing embryos and then turn off as we age.

Amazingly, damaged neurons in the eyes of mice injected with the three cells rejuvenated, even growing new axons, or projections from the eye into the brain.

Since that original study, Sinclair said his lab has reversed ageing in the muscles and brains of mice and is now working on rejuvenating a mouses entire body.

That discovery indicates there is a back-up copy of youthfulness information stored in the body, he added.

I call it the information theory of ageing, he said.

Its a loss of information that drives ageing cells to forget how to function, to forget what type of cell they are. And now we can tap into a reset switch that restores the cells ability to read the genome correctly again, as if it was young.

See more here:
Scientists have figured out how to reverse the ageing process in mice. Now theyre turning their attention to humans - 7NEWS

Posted in Stem Cell Videos | Comments Off on Scientists have figured out how to reverse the ageing process in mice. Now theyre turning their attention to humans – 7NEWS

Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market – BioSpace

Posted: June 13, 2022 at 2:20 am

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global regenerative medicine market for the historical period 20172018 and forecast period 20212028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period

Rise in Prevalence of Chronic Diseases, Genetic Disorders, and Cancer: Key Driver

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Key Players Increased Investment in Research & Development of Regenerative Medicine

Get COVID-19 Analysis on Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=419

Costly Treatment Associated with Regenerative Medicine

Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=419

Regenerative Medicine Market: Competition Landscape

More Trending Reports by Transparency Market Research

Dermal Fillers Market: https://www.transparencymarketresearch.com/dermal-fillers-market.html

Vascular Injury Treatment Market: https://www.transparencymarketresearch.com/vascular-injury-treatment-market.html

Hepatorenal Syndrome Treatment Market: https://www.transparencymarketresearch.com/hepatorenal-syndrome-treatment-market.html

Surgical Glue Market: https://www.transparencymarketresearch.com/surgical-glue-market.html

Ultrasound Gels Market: https://www.transparencymarketresearch.com/ultrasound-gel-market.html

Diabetic Foot Ulcers Treatment Market: https://www.transparencymarketresearch.com/diabetic-foot-ulcers-treatment-market.html

Menopausal Hot Flashes Market: https://www.transparencymarketresearch.com/menopausal-hot-flashes.html

Orthobiologics Market: https://www.transparencymarketresearch.com/orthobiologics-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read more from the original source:
Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market - BioSpace

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market – BioSpace

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma -…

Posted: June 13, 2022 at 2:20 am

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-501A in relapsed/refractory LBCL. The RMAT designation was based on the potential of ALLO-501A to address the unmet need for patients who have failed other therapies.

The designation for ALLO-501A supports the patient need for access to an off-the-shelf CAR T product that can be delivered faster, more reliably, and at greater scale, said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. Patients who are eligible for autologous CAR T therapy are often faced with treatment delays and manufacturing failures, placing them at risk for disease progression and disease-related complications. We look forward to initiating our pivotal trial on ALLO-501A and making this innovative product candidate readily available to patients.

Results from the ALPHA2 study were presented at an oral session of the American Society of Hematology (ASH) annual meeting in December 2021. Data support the potential of ALLO-501A to provide a safe and durable alternative to approved autologous CAR T therapies in CAR T nave patients.

Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the development and review processes for promising pipeline products, including cell therapies, that includes all the benefits of Fast Track and Breakthrough designation. An investigational cell therapy is eligible for RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life-threatening disease; and preliminary clinical evidence indicates that the therapy has the potential to address unmet medical needs for that disease. Advantages of the RMAT designation include early interactions with FDA that may be used to discuss potential surrogate or intermediate endpoints and potential ways to satisfy post approval requirements.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visitwww.allogene.comand follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as predicts, believes, potential, proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of future events or outcomes to identify these forward- looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the ALPHA2 trial of ALLO-501A, including initiating a pivotal clinical trial of ALLO-501A, which remains subject to further patient follow-up and discussions with the U.S. Food and Drug Administration; the ability to commercialize ALLO-501A; clinical outcomes, which may materially change as patient enrollment continues and more patient data become available; and the potential benefits of AlloCAR T. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with theSEC, including without limitation in its Form 10-Q for the quarter endedMarch 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogenes AlloCAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Source: Allogene Therapeutics, Inc.

Read more from the original source:
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma -...

Posted in Regenerative Medicine | Comments Off on Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma -…

Declining Stock and Solid Fundamentals: Is The Market Wrong About China Regenerative Medicine International Limited (HKG:8158)? – Simply Wall St

Posted: June 13, 2022 at 2:20 am

China Regenerative Medicine International (HKG:8158) has had a rough three months with its share price down 12%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study China Regenerative Medicine International's ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

See our latest analysis for China Regenerative Medicine International

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) Shareholders' Equity

So, based on the above formula, the ROE for China Regenerative Medicine International is:

44% = HK$49m HK$112m (Based on the trailing twelve months to March 2022).

The 'return' is the profit over the last twelve months. So, this means that for every HK$1 of its shareholder's investments, the company generates a profit of HK$0.44.

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

First thing first, we like that China Regenerative Medicine International has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 8.1% which is quite remarkable. This likely paved the way for the modest 17% net income growth seen by China Regenerative Medicine International over the past five years. growth

Next, on comparing with the industry net income growth, we found that China Regenerative Medicine International's growth is quite high when compared to the industry average growth of 12% in the same period, which is great to see.

Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if China Regenerative Medicine International is trading on a high P/E or a low P/E, relative to its industry.

China Regenerative Medicine International doesn't pay any dividend, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.

In total, we are pretty happy with China Regenerative Medicine International's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company. Our risks dashboard would have the 2 risks we have identified for China Regenerative Medicine International.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Follow this link:
Declining Stock and Solid Fundamentals: Is The Market Wrong About China Regenerative Medicine International Limited (HKG:8158)? - Simply Wall St

Posted in Regenerative Medicine | Comments Off on Declining Stock and Solid Fundamentals: Is The Market Wrong About China Regenerative Medicine International Limited (HKG:8158)? – Simply Wall St

Page 409«..1020..408409410411..420430..»